Not all sufferers with CLL need therapy. In spite of all the latest innovations, the iwCLL continue to endorses watchful observation for patients with asymptomatic disorder.86 This advice relies on at least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 The two trials https://solangem319emu5.tusblogos.com/profile